Shares of ImmuCell Co. (NASDAQ:ICCC - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.99 and traded as high as $6.65. ImmuCell shares last traded at $6.52, with a volume of 20,435 shares traded.
ImmuCell Stock Up 1.3%
The company has a 50-day moving average of $5.38 and a 200-day moving average of $5.03. The company has a current ratio of 3.11, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $57.29 million, a price-to-earnings ratio of -12.68 and a beta of 0.23.
ImmuCell (NASDAQ:ICCC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported $0.16 EPS for the quarter. The firm had revenue of $8.07 million during the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%.
Institutional Investors Weigh In On ImmuCell
A number of large investors have recently made changes to their positions in the stock. Mesirow Financial Investment Management Inc. lifted its position in ImmuCell by 100.0% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company's stock worth $125,000 after acquiring an additional 12,178 shares during the period. Citadel Advisors LLC acquired a new stake in shares of ImmuCell during the fourth quarter worth about $149,000. Northern Trust Corp boosted its position in ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after buying an additional 14,982 shares during the last quarter. Geode Capital Management LLC increased its holdings in ImmuCell by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock worth $332,000 after buying an additional 7,878 shares during the period. Finally, Dauntless Investment Group LLC acquired a new position in ImmuCell in the 4th quarter worth approximately $676,000. 13.47% of the stock is owned by hedge funds and other institutional investors.
ImmuCell Company Profile
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Featured Articles
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
